AngioDynamics to Present at Canaccord Genuity 34th Annual Growth Conference

Loading...
Loading...

ALBANY, N.Y., Aug. 7, 2014 (GLOBE NEWSWIRE) -- AngioDynamics ANGO, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014, at 8 a.m. (ET). The conference will be held at the InterContinental Hotel in Boston.

A live audio and/or webcast and subsequent archived replay of AngioDynamics' presentation may be accessed via the investor relations section of the Company's website under "Events & Presentations" at http://investors.angiodynamics.com/events.cfm. The replay will be available for 90 days after the event.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

CONTACT: Company Contact: AngioDynamics, Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Michael Polyviou/Robert Jones (212) 850-6020; (646) 201-5447 mpolyviou@evcgroup.com; bjones@evcgroup.com Media Contact: EVC Group, Inc. Dave Schemelia (646) 201-5431 dave@evcgroup.com
Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...